NCT07671391Not yet recruitingPhase 2
A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants
A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body Composition in Obese Participants
Source: ClinicalTrials.gov · Last updated 26 Jun 2026
Brief summary (registry, in English)
This study is a randomized, double-blind, placebo-controlled trial aimed at exploring the effects of LAE102 injection in combination with Tirzepatide on body composition.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 28 May 2026
- Start date
- Aug 2026
- Primary completion date
- Jul 2027
- Lead sponsor
- Shanghai Zhongshan Hospital
- Diseases
- Obesity
- NCT number
- NCT07671391
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 60
- From Aug 2026 to the primary completion date, Jul 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously underwent surgical or endoscopic weight loss metabolic surgery (except for local liposuction within 1 year before screening) or gastric balloon implantation, or planned to undergo any weight loss surgery or receive other weight loss treatments during the study;
Other illness
- A clear diagnosis of type 1, type 2 diabetes or other types of diabetes (excluding gestational diabetes);
- Uncontrolled thyroid disease, or screening criteria.
Lab values
- Screening criteria: Glycated hemoglobin ≥ 6.5% or fasting blood glucose ≥ 7.0 mmol/L.
- Obesity related:
Other
- Diagnosed with secondary obesity;
Who the study is looking for
- Voluntarily participate in the study and sign the Informed Consent Form (ICF);
- Male or female participants aged between 18 and 75 years (inclusive) at the time of signing the ICF;
- BMI ranging from 28.0 to 40.0 kg/m2 during the screening;
- Self-reporting at least one experience of weight loss failure after adjusting diet and exercise, and within the previous 3 months, the weight change after only dietary and exercise adjustments was less than 5%;
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.